TW202245746A - Ｎ－（（ｒ）－２，３－二羥基丙氧基）—３，４—二氟—２—（２—氟—４—碘—苯基胺基)—苯甲醯胺之基本上純的形式ｉｖ之組合物及其用途 - Google Patents

Ｎ－（（ｒ）－２，３－二羥基丙氧基）—３，４—二氟—２—（２—氟—４—碘—苯基胺基)—苯甲醯胺之基本上純的形式ｉｖ之組合物及其用途 Download PDF

Info

Publication number
TW202245746A
TW202245746A TW111105793A TW111105793A TW202245746A TW 202245746 A TW202245746 A TW 202245746A TW 111105793 A TW111105793 A TW 111105793A TW 111105793 A TW111105793 A TW 111105793A TW 202245746 A TW202245746 A TW 202245746A
Authority
TW
Taiwan
Prior art keywords
fluoro
dihydroxypropoxy
difluoro
phenylamino
benzamide
Prior art date
Application number
TW111105793A
Other languages
English (en)
Chinese (zh)
Inventor
爾文 厄丹恩
Original Assignee
美商華納蘭茂公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商華納蘭茂公司 filed Critical 美商華納蘭茂公司
Publication of TW202245746A publication Critical patent/TW202245746A/zh

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
    • C07C259/04—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
    • C07C259/10—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to carbon atoms of six-membered aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
TW111105793A 2021-02-17 2022-02-17 Ｎ－（（ｒ）－２，３－二羥基丙氧基）—３，４—二氟—２—（２—氟—４—碘—苯基胺基)—苯甲醯胺之基本上純的形式ｉｖ之組合物及其用途 TW202245746A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/US2021/018378 WO2022177556A1 (fr) 2021-02-17 2021-02-17 Compositions de forme iv essentiellement pure de n-((r)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodophénylamino)-benzamide et leurs utilisations
WOPCT/US21/18378 2021-02-17

Publications (1)

Publication Number Publication Date
TW202245746A true TW202245746A (zh) 2022-12-01

Family

ID=74860567

Family Applications (1)

Application Number Title Priority Date Filing Date
TW111105793A TW202245746A (zh) 2021-02-17 2022-02-17 Ｎ－（（ｒ）－２，３－二羥基丙氧基）—３，４—二氟—２—（２—氟—４—碘—苯基胺基)—苯甲醯胺之基本上純的形式ｉｖ之組合物及其用途

Country Status (10)

Country Link
EP (1) EP4294789A1 (fr)
JP (1) JP2024507822A (fr)
KR (1) KR20230148177A (fr)
CN (1) CN117500781A (fr)
AR (1) AR124907A1 (fr)
AU (1) AU2021428932A1 (fr)
CA (1) CA3211395A1 (fr)
IL (1) IL304974A (fr)
TW (1) TW202245746A (fr)
WO (1) WO2022177556A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023223205A1 (fr) 2022-05-17 2023-11-23 Teva Pharmaceuticals International Gmbh Formes à l'état solide de mirdamétinib et leur procédé de préparation

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001273498B2 (en) 2000-07-19 2006-08-24 Warner-Lambert Company Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids
CA2542210A1 (fr) 2003-10-21 2005-05-06 Warner-Lambert Company Llc Forme polymorphe du n-[(r)-2,3-dihydroxy-propoxy]-3,4-difluoro-2-fluoro-4-iodophenylamino)-benzamide
WO2006134469A1 (fr) 2005-06-14 2006-12-21 Warner-Lambert Company Llc Procedes de preparation d'un inhibiteur de mek

Also Published As

Publication number Publication date
AR124907A1 (es) 2023-05-17
EP4294789A1 (fr) 2023-12-27
KR20230148177A (ko) 2023-10-24
JP2024507822A (ja) 2024-02-21
CN117500781A (zh) 2024-02-02
WO2022177556A1 (fr) 2022-08-25
AU2021428932A1 (en) 2023-09-21
IL304974A (en) 2023-10-01
CA3211395A1 (fr) 2022-08-25

Similar Documents

Publication Publication Date Title
US11453641B2 (en) Methods of treating neurofibromatosis with N-((R)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-benzamide
AU2014239995B2 (en) Salt of omecamtiv mecarbil and process for preparing salt
TW419471B (en) Morpholine derivatives useful as tachykinin receptor antagonists, preparation thereof and pharmaceutical composition containing same
RU2376294C2 (ru) ПОЛИМОРФНАЯ МОДИФИКАЦИЯ СОЕДИНЕНИЯ {6,7-БИС(2-МЕТОКСИЭТОКСИ)ХИНАЗОЛИН-4-ИЛ}-(3e)
JP2005516009A (ja) 重水素化された置換ピラゾリル−ベンゼンスルホンアミド並びにこれを含有する医薬品
EP2603503A1 (fr) Mésylate de dabigatran étexilate, ses formes solides et leurs procédés de préparation
US20230330047A1 (en) Dispersible formulations of n-((r)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2- fluoro-4-iodo-phenylamino)-benazmide and uses thereof
JP2024517431A (ja) （ｓ）－ｎ－（３－（２－（（（ｒ）－１－ヒドロキシプロパン－２－イル）アミノ）－６－モルホリノピリジン－４－イル）－４－メチルフェニル）－３－（２，２，２－トリフルオロエチル）ピロリジン－１－カルボキサミドおよびその塩の固体状態での形態
TW202245746A (zh) Ｎ－（（ｒ）－２，３－二羥基丙氧基）—３，４—二氟—２—（２—氟—４—碘—苯基胺基)—苯甲醯胺之基本上純的形式ｉｖ之組合物及其用途
TWI815820B (zh) ２－（５－（４－（２－嗎啉乙氧基）苯基）吡啶－２－基）－ｎ－芐乙醯胺之固態形式
JP2022513925A (ja) ＴＧＦβ阻害薬の新規多形体
US20110269838A1 (en) Novel processes and pure polymorphs
TW202200594A (zh) 一種glp-1受體激動劑的晶型a及其製備方法
JPH02306962A (ja) 新規ｎ―置換―１―デオキシノジリマイシン誘導体及びそれを含有する癌細胞転移抑制剤
JP2018515566A (ja) 医薬組成物
US8754129B2 (en) Crystalline vorinostat form VI
TW202245745A (zh) Ｎ－（（ｒ）－２，３－二羥基丙氧基）－３，４－二氟－２－（２－氟－４－碘－苯基胺基）－苯甲醯胺之可分散調配物及其用途
US20220089550A1 (en) Crystalline forms of (s)-2-(7-cyano-1h-benzimidazol-1 yl)-n-{1-[4-(1-cyano-1-methylethyl)phenyl]ethyl}acetamide
CA3218813A1 (fr) Composes indenes, compositions pharmaceutiques a base de ceux-ci et leurs applications therapeutiques